Showing results (201-210 of 280) with videos related to
Sort By:
Pageof 28
Prostate Cancer and Prostatic Diseases|August 5, 2026
Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancerJane McKenzie, Lauren Howard, Joseph J Park, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 7, 2020
Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future DirectionsEmily M Rencsok, Latifa A Bazzi, Rana R McKay, et al.Journal of Oncology Practice|August 15, 2013
Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measureKaren A Autio, Antonia V Bennett, Xiaoyu Jia, et al.Biorxiv : the Preprint Server for Biology|April 1, 2025
Resilience and vulnerabilities of tumor cells under purine shortage stressJianpeng Yu, Chen Jin, Cheng Su, et al.Cancer Immunology, Immunotherapy : CII|March 2, 2024
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancerGerald S Falchook, James Reeves, Sunil Gandhi, et al.Clinical Genitourinary Cancer|June 3, 2020
PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial CarcinomaLandon C Brown, Jason Zhu, Matthew K Labriola, et al.European Urology|August 25, 2012
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settingsCora N Sternberg, Joaquim Bellmunt, Guru Sonpavde, et al.Prostate Cancer and Prostatic Diseases|March 16, 2022
A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancerLandon C Brown, Susan Halabi, Jason A Somarelli, et al.Clinical Genitourinary Cancer|May 20, 2022
Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer AgentsLisa P Spees, Michaela A Dinan, Bradford E Jackson, et al.Journal for Immunotherapy of Cancer|January 31, 2018
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinomaVadim S Koshkin, Pedro C Barata, Tian Zhang, et al.Pageof 28